Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Prognosis & advances in treatment strategies for SF3B1-mutant MDS

Michaela Fontenay • 5 May 2023
MDS 2023
Myelodysplastic Syndromes Imetelstat Luspatercept

Michaela Fontenay, MD, PhD, Cochin Hospital, Paris, France, comments on the impact of SF3B1 mutations in myelodysplastic syndromes (MDS), highlighting the potential of targeting DNA replication stress in these patients, and discussing recent advances in treatments for patients with SF3B1-mutant MDS resistant to luspatercept. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals